Evidence map›Paper›PMID 36017395›Full record

ArticleBioMed research international2022

Negative-High Titer of

Jun Lu, Dong Van Hoang, Yuko Hayashi, Makiko Hashimoto, Sachiko Kubo, Hiroshi Kajio, Tetsuya Mizoue

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Frontiers in endocrinology · 2026
    Article
  2. Article
  3. Frontiers in cellular and infection microbiology · 2025
    Article
  4. The influence ofFrontiers in cellular and infection microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jun LuDepartment of Medical Examination Center, Hospital of National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655, Japan.ORCID https://orcid.org/0000-0001-9828-3640
Dong Van HoangDepartment of Epidemiology and Prevention, Center for Clinical Sciences, Hospital of National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655, Japan.
Yuko HayashiDepartment of Medical Examination Center, Hospital of National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655, Japan.
Makiko HashimotoDepartment of Medical Examination Center, Hospital of National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655, Japan.
Sachiko KuboDepartment of Medical Examination Center, Hospital of National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655, Japan.
Hiroshi KajioDepartment of Medical Examination Center, Hospital of National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655, Japan.
Tetsuya MizoueDepartment of Epidemiology and Prevention, Center for Clinical Sciences, Hospital of National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo 162-8655, Japan.
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Materials and Methods: We surveyed 2,478 people who underwent a Ningen Dock examination and had serological HP antibody data, from May 2016 to December 2020 at National Center for Global Health and Medicine, Tokyo, Japan. Multiple regression models were used to quantify the association between HP antibody titer and serum lipid levels. Results: The adjusted odds ratio (95% confidence interval [CI]) for dyslipidemia in HP negative-high and positive titer was 1.24 (0.96, 1.79) and 1.36 (1.10, 1.68), respectively, compared with HP negative-low titer; Conclusion: The present cross-sectional study suggests that a HP negative-high antibody titer may be associated with dyslipidemia, HDL-C, and LDL-C to HDL-C ratio among Japanese Ningen Dock's participants.

Indexed as

DyslipidemiasHelicobacter InfectionsHelicobacter pyloriAntibodies, BacterialCholesterol, HDLCholesterol, LDLCross-Sectional StudiesHumansAntibodies, BacterialCholesterol, HDLCholesterol, LDL

Identifiers

PMID36017395
PMCPMC9398768
OpenAlexW4292308104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.